These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 27245697)

  • 1. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
    Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
    J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.
    Zou P; Xu H; Chen P; Yan Q; Zhao L; Zhao P; Gu A
    PLoS One; 2013; 8(7):e68782. PubMed ID: 23894344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate Dehydrogenase
    Murugan AK; Alzahrani AS
    Br J Biomed Sci; 2022; 79():10208. PubMed ID: 35996504
    [No Abstract]   [Full Text] [Related]  

  • 7. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
    Kloosterhof NK; Bralten LB; Dubbink HJ; French PJ; van den Bent MJ
    Lancet Oncol; 2011 Jan; 12(1):83-91. PubMed ID: 20615753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
    Houillier C; Wang X; Kaloshi G; Mokhtari K; Guillevin R; Laffaire J; Paris S; Boisselier B; Idbaih A; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
    Neurology; 2010 Oct; 75(17):1560-6. PubMed ID: 20975057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH2 mutation in gliomas including novel mutation.
    Koh J; Cho H; Kim H; Kim SI; Yun S; Park CK; Lee SH; Choi SH; Park SH
    Neuropathology; 2015 Jun; 35(3):236-44. PubMed ID: 25495392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
    Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
    Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors.
    Schenkel LC; Mathew J; Hirte H; Provias J; Paré G; Chong M; Grafodatskaya D; McCready E
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
    Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P
    World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population.
    Malueka RG; Dwianingsih EK; Bayuangga HF; Panggabean AS; Argo IW; Donurizki AD; Shaleh S; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2287-2295. PubMed ID: 32856857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1 and IDH2 mutations in gliomas.
    Yan H; Parsons DW; Jin G; McLendon R; Rasheed BA; Yuan W; Kos I; Batinic-Haberle I; Jones S; Riggins GJ; Friedman H; Friedman A; Reardon D; Herndon J; Kinzler KW; Velculescu VE; Vogelstein B; Bigner DD
    N Engl J Med; 2009 Feb; 360(8):765-73. PubMed ID: 19228619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
    Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
    J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
    Labussière M; Idbaih A; Wang XW; Marie Y; Boisselier B; Falet C; Paris S; Laffaire J; Carpentier C; Crinière E; Ducray F; El Hallani S; Mokhtari K; Hoang-Xuan K; Delattre JY; Sanson M
    Neurology; 2010 Jun; 74(23):1886-90. PubMed ID: 20427748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
    Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
    J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
    Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
    J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.